These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

852 related articles for article (PubMed ID: 30470252)

  • 1. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.
    Verma V; Sprave T; Haque W; Simone CB; Chang JY; Welsh JW; Thomas CR
    J Immunother Cancer; 2018 Nov; 6(1):128. PubMed ID: 30470252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
    Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
    Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
    Oh A; Tran DM; McDowell LC; Keyvani D; Barcelon JA; Merino O; Wilson L
    J Manag Care Spec Pharm; 2017 Jun; 23(6):653-664. PubMed ID: 28530525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies.
    da Veiga CRP; da Veiga CP; Drummond-Lage AP
    Crit Rev Oncol Hematol; 2018 Sep; 129():133-145. PubMed ID: 30097232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting.
    Pike E; Hamidi V; Saeterdal I; Odgaard-Jensen J; Klemp M
    BMJ Open; 2017 Aug; 7(8):e014880. PubMed ID: 28827234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
    Ding H; Xin W; Tong Y; Sun J; Xu G; Ye Z; Rao Y
    PLoS One; 2020; 15(9):e0238536. PubMed ID: 32877435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview.
    Wu C; Li W; Tao H; Zhang X; Xin Y; Song R; Wang K; Zuo L; Cai Y; Wu H; Hui W
    Crit Rev Oncol Hematol; 2024 Jan; 193():104195. PubMed ID: 37931769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆.
    Ward MC; Shah C; Adelstein DJ; Geiger JL; Miller JA; Koyfman SA; Singer ME
    Oral Oncol; 2017 Nov; 74():49-55. PubMed ID: 29103751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
    Tan PS; Aguiar P; Haaland B; Lopes G
    Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
    Chai QQ; Du JY; Zhu J; Wu B
    Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
    Ali AK; Watson DE
    Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.
    Bohensky MA; Pasupathi K; Gorelik A; Kim H; Harrison JP; Liew D
    Value Health; 2016 Dec; 19(8):1009-1015. PubMed ID: 27987627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
    Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
    Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
    Ivashko IN; Kolesar JM
    Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Not Available].
    Pagès C; Baroudjian B; Lebbé C
    Bull Cancer; 2016 Nov; 103 Suppl 1():S132-S137. PubMed ID: 28057176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.
    Matter-Walstra K; Schwenkglenks M; Aebi S; Dedes K; Diebold J; Pietrini M; Klingbiel D; von Moos R; Gautschi O;
    J Thorac Oncol; 2016 Nov; 11(11):1846-1855. PubMed ID: 27311996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
    Carbognin L; Pilotto S; Milella M; Vaccaro V; Brunelli M; Caliò A; Cuppone F; Sperduti I; Giannarelli D; Chilosi M; Bronte V; Scarpa A; Bria E; Tortora G
    PLoS One; 2015; 10(6):e0130142. PubMed ID: 26086854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.